Eli Lilly continues genetic medicine push with $1.9bn Ascidian partnership - Pharmaceutical Technology

Eli Lilly’s deal with Ascidian is one of several that the pharma giant has cut within the realm of genetic medicines. Lilly’s deal with Ascidian is one of several that the pharma giant has cut within the realm of genetic medicines. Lilly’s deal with Ascidian is one of several genetic medicine-centric deals the pharma giant has signed in recent months. Credit: ART-ur / Shutterstock.com. Eli Lilly has penned a research collaboration deal with Massachusetts-based biotech, Ascidian Therapeutics, to discover and develop drugs for kidney diseases – adding another bead to the string of genetic medicine-focused deals Lilly has signed over…

Source: Pharmaceutical Technology